SecBot SecBot

DCOY

Decoy Therapeutics Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001615219 Biotech & Drug Discovery
$1.03 +0.11 (+12.50%)
Oct 27 4:00 PM ET · prev $0.9200
Market cap
$2.3M
Nano cap
Median target
$3.00
+190% · range $3.00–3.00
Next earnings
Nov 12
in 16 days · EPS est. −$2.59
1 year
−97.7%
from $45.96 · Oct 27
30 days
−55.2%
from $2.31
52-week range
$0.9200–46.68
−98% from high · low Oct 26
Avg volume 20D
94.9K
Oct 2 spike 252.0K
Short interest
🔒 Subscribers only
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
11
analyzed by SecBot
SecBot read BEARISH 4 reports · 90 days
Balance 2 bearish · 0 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 4/4 ·Next Earnings date, Nov 12, 2026
Strongest BEARISH Decoy Therapeutics filed an S-1 registration statement to register up to 2,368,868 shares of common stock…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q2 2026: 0 added (0 new), 1 trimmed or exited.

  • EstimatesRISING

    Current-quarter EPS estimate −$3.120 → −$2.590 over 90 days.

  • TrendDOWNTREND

    55% below its 50-day average. New closing low $0.9200 on Oct 26.

  • SocialQUIET

    No Reddit mentions this week. Last mention Sep 28.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
UBS Group AGNEAR_EXIT25$180.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Jan 2026
12-month targets · 1 analysts

Price is below the lowest target. Median implies +190%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Jan 23, 2026Ladenburg Thalmann
INITIATE
INITIATEBuy
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 19, 2026 SEC
The SEC declared effective the S-1 registration statement (File No. 333-299353) for Decoy Therapeutics Inc. on October…
EFFECT — Impact 4/10
Oct 7, 2026 SEC
Decoy Therapeutics filed an S-1 registration statement to register up to 2,368,868 shares of common stock for resale…
S-1 — Impact 6/10
Sep 30, 2026 Other
Decoy Therapeutics to Present at The Small Cap Showcase
CEO Rick Pierce to deliver an investor presentation on Thursday, October 1 in New York CEO Rick Pier
Sep 23, 2026 SEC
Decoy Therapeutics entered into a warrant inducement agreement with Armistice Capital Master Fund Ltd. to immediately…
8-K — Impact 6/10
Aug 31, 2026 Insider
HANISH ARNOLD C was granted 3,000 shares
Director
Aug 31, 2026 Insider
Lammers Paul was granted 2,000 shares
Director
Aug 31, 2026 Insider
McVicar William K. was granted 3,000 shares
Director
Jun 30, 2026 Inst.
UBS Group AG — NEAR_EXIT
25 shares ($180.00)

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Aug 31, 2026
HANISH ARNOLD C
Director
AWARD3,000 sh
Aug 31, 2026
Lammers Paul
Director
AWARD2,000 sh
Aug 31, 2026
McVicar William K.
Director
AWARD3,000 sh
Aug 31, 2026
Gauthier Patricia G.
Director
AWARD2,000 sh
Aug 31, 2026
Burleson Tess
Director
AWARD2,000 sh
Aug 31, 2026
PIERCE FREDERICK II
Chief Executive Officer
AWARD33,455 sh
Aug 31, 2026
Rosenblum Mark J
Chief Financial Officer
AWARD9,682 sh
Aug 31, 2026
Marschel Peter Klaus
Chief Business Officer
AWARD3,900 sh

Earnings setup

Estimates
Nov 12
reports in 16 days
−$2.59
EPS estimate, this quarter
+17%
estimate change, 90 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$2.59-$2.59–-$2.59—$0.00
Next Q-$1.11-$1.11–-$1.11—$0.00
Current FY-$8.96-$8.96–-$8.96—$0.00
Next FY-$8.28-$8.28–-$8.28—$0.00

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Trading halts
Sep 22, 2026Volatility PauseResumed
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 12, 2026
Earnings date
DCOY Q3 2026 Earnings Scheduled — 2026-11-12
Recent
Sep 30, 2026
Press release
Decoy Therapeutics to Present at The Small Cap Showcase
CEO Rick Pierce to deliver an investor presentation on Thursday, October 1 in New York CEO Rick Pierce to deliver an investor presentation on…
Sep 22, 2026
Press release
Decoy Therapeutics, Inc. Issues Correction to Warrant Inducement Transaction Press Release
HOUSTON, Sept. 22, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY) (the "Company" or "Decoy"), today issued a correction to its press…
Sep 22, 2026
Trading halt
Halt Resumed: DCOY — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-09-22T16:51:40.000Z | Resumed 2026-09-22T16:56:40.000Z
Sep 22, 2026
Trading halt
Trading Halt: DCOY — LUDP (Volatility Trading Pause)
Decoy Therapeutics Cmn | Market: NASDAQ | Code: LUDP — Volatility Trading Pause
Sep 22, 2026
Press release
Decoy Therapeutics, Inc. Announces a Warrant Inducement Transaction for $3.85 Million in Gross Proceeds Priced At-The-Market under Nasdaq Rules
HOUSTON, Sept. 22, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY) ("the Company" or "Decoy"), a biotechnology company pioneering…
Reddit
Recent posts
r/stocks Neutral 29d ago
DCOY after the collapse and warrant dilution: worth holding or is this a dilution trap?
1 upvotes · 0 comments
All social signals and their track records

SecBot reports

11 filings · 0 bullish · 3 bearish · 1 mixed · 7 neutral
All DCOY filing & press-release reports (11)